Trevi Therapeutics Inc. trades on the NASDAQ under the symbol “TRVI,” is a biotechnology business. In a research report published on November 22, investment analysts from SVB Leerink provided their projections for Trevi Therapeutics’ earnings for the fiscal year 2024. According to T. According to Smith at SVB Leerink, the company is projected to generate $0.59 in earnings per share this year. The company has an “Outperform” rating from SVB Leerink, and its price target is $6.00. The current average estimate places Trevi Therapeutics’ full-year earnings at $0.55 per share, which is the amount that is predicted to be earned by the company. Additionally, SVB Leerink projects that Trevi Therapeutics will have earnings of $0.83 per share for the fiscal year ending in 2025.
Recently, interest in TRVI has been voiced by representatives from other brokerages. For example, Needham & Company LLC lowered their price objective on Trevi Therapeutics from $10.00 to $8.00 and gave the company a “buy” rating in a report published on Friday, November 11. In addition, the price objective that Oppenheimer has set for Trevi Therapeutics has been lowered to $9.00, according to a research report that was published on Thursday, November 17.
TRVI began trading at $1.87 on Wednesday. The firm’s market cap is $112.05 million; it has a price-to-earnings ratio of -2.40, and a beta of 0.75. The stock price has a simple moving average of fifty days of $2.01, and its simple moving average of two hundred days is $2.64. The all-time high for Trevi Therapeutics over the past 52 weeks is $4.68, and its all-time low is $0.46. The debt-to-equity ratio comes in at 0.03, while the quick and current ratios come in at 8.70.
Trevi Therapeutics (NASDAQ: TRVI) disclosed its most recent quarterly results report on November 10, making it available for public consumption. The company announced earnings per share of $0.12 for the quarter, which was $0.03 higher than the consensus expectation of $0.15 for the loss.
Substantial months have seen several significant shareholders in the corporation make recent shifts in their holdings. During the first three months of 2018, Commonwealth Equity Services LLC purchased about 33 thousand dollars worth of Trevi Therapeutics stock. A 245.6% increase in WealthTrust Axiom LLC’s investment in Trevi Therapeutics was achieved during the first quarter of 2018. After making new purchases over the time frame in question, WealthTrust Axiom LLC now holds 98,500 shares of the firm’s stock, giving the company a market value of $216,000 overall. In the first three months of 2018, MAI Capital Management purchased a new position in Trevi Therapeutics that was valued at about $3,391,000. Vanguard Group Inc. grew its holdings in Trevi Therapeutics by 7.6% during the first quarter of the fiscal year. Following the acquisition of 10,780 extra shares over the time frame in question, Vanguard Group Inc. now holds 152,831 shares of the company’s stock, which has a value of $336,000. Finally, at the end of the first quarter, State Street Corporation completed the purchase of a new 81,000-dollar investment in Trevi Therapeutics.
Trevi Therapeutics, Inc. is a biopharmaceutical company in the clinical stage dedicated to developing and commercializing Haduvio as a treatment for severe neurologically mediated illnesses. The firm is developing Haduvio, an oral extended-release formulation of nalbuphine that is now participating in phase IIb/III clinical trials for treating chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis.